Identifying developmental toxicity pathways for a subset of ToxCast chemicals using human embryonic stem cells and metabolomics

Toxicology and Applied Pharmacology

Volumn 257, Issue 1, 2011, Pages 111-121

  Kleinstreuer, N C ^b   Smith, A M ^a   West, P R ^a   Conard, K R ^a   Fontaine, B R ^a   Weir Hauptman, A M ^d   Palmer, J A ^a   Knudsen, T B ^b   Dix, D J ^b   Donley, E L R ^a   Cezar, G G ^a,c  

^a Stemina Biomarker Discovery Inc   (United States)

^b U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d 206 Carnegie Center   (United States)

Author keywords

Developmental toxicity; Human embryonic stem cells; Metabolomics; Predictive model

Indexed keywords

2 (4 ISOPROPYL 4 METHYL 5 OXO 2 IMIDAZOLIN 2 YL)NICOTINATE ISOPROPYLAMMONIUM; 4,4' ISOPROPYLIDENEDIPHENOL; ARGININE; BIFENAZATE; BUTRALIN; CHEMICAL TERATOGEN; COENZYME A; FLUAZINAM; FLUSILAZOLE; GLUTATHIONE; IMAZAMOX; NICOTINAMIDE; NICOTINIC ACID; PANTOTHENIC ACID; PROLINE; PYRIDABEN; S BIOALLETHRIN; TOXIC SUBSTANCE; TRICLOSAN; UNCLASSIFIED DRUG;

ACCURACY; ADVERSE OUTCOME; AMINO ACID METABOLISM; ARTICLE; BIOSYNTHESIS; CHEMICAL TERATOGENESIS; CONTROLLED STUDY; DEVELOPMENTAL TOXICITY; EMBRYONIC STEM CELL; GLUTATHIONE METABOLISM; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; METABOLITE; METABOLOMICS; PREDICTIVE VALUE; SUPERNATANT; TERATOGENICITY;

ARGININE; COENZYME A; EMBRYONIC STEM CELLS; GLUTATHIONE; HUMANS; METABOLOMICS; NIACIN; NIACINAMIDE; PANTOTHENIC ACID; PROLINE; TOXICITY TESTS;

ANIMALIA; MAMMALIA;

EID: 81255159025     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2011.08.025     Document Type: Article

References (60)

1. (NTP), N.T.P. NTP-CERHR monograph on the potential human reproductive and developmental effects of bisphenol A. NTP CERHR MON 2008, i-III1.
2. Baker H., Frank O., Thomson A.D., Langer A., Munves E.D., De Angelis B., Kaminetzky H.A. Vitamin profile of 174 mothers and newborns at parturition. Am. J. Clin. Nutr. 1975, 28:59-65.
3. Barrier M., Jeffay S., Nichols H.P., Chandler K.J., Hoopes M.R., Slentz-Kesler K., et al. Mouse embryonic stem cell adherent cell differentiation and cytotoxicity (ACDC) assay. Reprod. Toxicol. 2011, 31(4):383-391.
4. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. Roy. Stat. Soc., Ser. B 1995, 57:289-300.
5. Benowitz N.L. Clinical pharmacology of caffeine. Annu. Rev. Med. 1990, 41:277-288.
6. Boman G. Serum concentration and half-life of rifampicin after simultaneous oral administration of aminosalicylic acid or isoniazid. Eur. J. Clin. Pharmacol. 1974, 7:217-225.
7. Brocks D.R. Anticholinergic drugs used in Parkinson's disease: an overlooked class of drugs from a pharmacokinetic perspective. J. Pharm. Pharm. Sci. 1999, 2:39-46.
8. Burstein A.H., Horton R.L., Dunn T., Alfaro R.M., Piscitelli S.C., Theodore W. Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers. Clin. Pharmacol. Ther. 2000, 68:605-612.
9. Cezar G.G., Quam J.A., Smith A.M., Rosa G.J., Piekarczyk M.S., Brown J.F., Gage F.H., Muotri A.R. Identification of small molecules from human embryonic stem cells using metabolomics. Stem Cells Dev. 2007, 16:869-882.
10. Chandler, K.J., Barrier, M., Jeffay, S., Nichols, H.P., Kleinstreuer, N.C., Singh, A.V., et al., 2011. Evaluation of 309 environmental chemicals using a mouse embryonic stem cell adherent cell differentiation and cytotoxicity assay. PLoS One 6 (6), e18540.
11. Chapin R.E., Stedman D.B. Endless possibilities: stem cells and the vision for toxicology testing in the 21st century. Toxicol. Sci. 2009, 112:17-22.
12. Chen T.L., Kennedy M.J., Anderson L.W., Kiraly S.B., Black K.C., Colvin O.M., Grochow L.B. Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Drug Metab. Dispos. 1997, 25:544-551.
13. Colburn W.A., Bekersky I., Blumenthal H.P. Dietary saccharin kinetics. Clin. Pharmacol. Ther. 1981, 30:558-563.
14. Daston G.P. Genomics and developmental risk assessment. Birth Defects Res. A Clin. Mol. Teratol. 2007, 79:1-7.
15. Daston G.P., Chapin R.E., Scialli A.R., Piersma A.H., Carney E.W., Rogers J.M., Friedman J.M. A different approach to validating screening assays for developmental toxicity. Birth Defects Res. B Dev. Reprod. Toxicol. 2010, 89:526-530.
16. Dix D.J., Houck K.A., Martin M.T., Richard A.M., Setzer R.W., Kavlock R.J. The ToxCast program for prioritizing toxicity testing of environmental chemicals. Toxicol. Sci. 2007, 95:5-12.
17. EPA, U.S. Reregistration Eligibility Decision for Triclosan 2010, 17. U.S. Environmental Protection Agency, Washington, DC, (table 13. Web).
18. Friedman H., Greenblatt D.J., Scavone J.M., Burstein E.S., Ochs H.R., Harmatz J.S., Shader R.I. Clearance of the antihistamine doxylamine. Reduced in elderly men but not in elderly women. Clin. Pharmacokinet. 1989, 16:312-316.
19. Gazala E., Sarov B., Hershkovitz E., Edvardson S., Sklan D., Katz M., Friger M., Gorodischer R. Retinol concentration in maternal and cord serum: its relation to birth weight in healthy mother-infant pairs. Early Hum. Dev. 2003, 71:19-28.
20. Genschow E., Spielmann H., Scholz G., Seiler A., Brown N., Piersma A., Brady M., Clemann N., Huuskonen H., Paillard F., Bremer S., Becker K. The ECVAM internationalvalidation study on in vitro embryotoxicity tests: results of the definitive phase and evaluation of prediction models. European Centre for the Validation of Alternative Methods. Altern. Lab. Anim. 2002, 30:151-176.
21. Genschow E., Spielmann H., Scholz G., Pohl I., Seiler A., Clemann N., Bremer S., Becker K. Validation of the embryonic stem cell test in the international ECVAM validation study on three in vitro embryotoxicity tests. Altern. Lab. Anim. 2004, 32:209-244.
22. Gwilt P.R., Tracewell W.G. Pharmacokinetics and pharmacodynamics of hydroxyurea. Clin. Pharmacokinet. 1998, 34:347-358.
23. Hansen J.M., Carney E.W., Harris C. Altered differentiation in rat and rabbit limb bud micromass cultures by glutathione modulating agents. Free Radic. Biol. Med. 2001, 31:1582-1592.
24. Hartung T. Toxicology for the twenty-first century. Nature 2009, 460:208-212.
25. Henschel O., Gipson K.E., Bordey A. GABAA receptors, anesthetics and anticonvulsants in brain development. CNS Neurol. Disord. Drug Targets 2008, 7:211-224.
26. Isibashi M., Akazawa S., Sakamake H., et al. Oxygen-induced embryopathy and the significance of glutathione-dependent antioxidant system in the rat embryo during early organogenesis. Free Radic. Biol. Med. 1997, 22:447-454.
27. Jackson A.A., Persaud C., Werkmeister G., McClelland I.S., Badaloo A., Forrester T. Comparison of urinary 5-l-oxoproline (l-pyroglutamate) during normal pregnancy in women in England and Jamaica. Br. J. Nutr. 1997, 77:183-196.
28. Judson R.S., Houck K.A., Kavlock R.J., Knudsen T.B., Martin M.T., Mortensen H.M., Reif D.M., Rotroff D.M., Shah I., Richard A.M., Dix D.J. In vitro screening of environmental chemicals for targeted testing prioritization: the ToxCast project. Environ. Health Perspect. 2010, 118:485-492.
29. Kalmbach R.D., Choumenkovitch S.F., Troen A.M., D'Agostino R., Jacques P.F., Selhub J. Circulating folic acid in plasma: relation to folic acid fortification. Am. J. Clin. Nutr. 2008, 88:763-768.
30. Kleinstreuer, N., Judson, R., Sipes, N., Reif, D., Singh, A., Chandler, K., DeWoskin, R., Dix, D., Kavlock, R., and Knudsen, T. (2011). Environmental Impact on Vascular Development Predicted by HTS (under revision). Environ. Health Perspect.
31. Knudsen T.B., Martin M.T., Kavlock R.J., Judson R.S., Dix D.J., Singh A.V. Profiling the activity of environmental chemicals in prenatal developmental toxicity studies using the U.S. EPA's ToxRefDB. Reprod. Toxicol. 2009, 28:209-219.
32. Levine M., Conry-Cantilena C., Wang Y., Welch R.W., Washko P.W., Dhariwal K.R., Park J.B., Lazarev A., Graumlich J.F., King J., Cantilena L.R. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:3704-3709.
33. Lu W., Zhu H., Wen S., Yang W., Shaw G., Lammer E., Finnell R. Nicotinamide N-methyl transferase (NNMT) gene polymorphisms and risk for spina bifida. Birth Defects Res. A Clin. Mol. Teratol. 2008, 82:670-675.
34. Martin M.T., Judson R.S., Reif D.M., Kavlock R.J., Dix D.J. Profiling chemicals based on chronic toxicity results from the U.S. EPA ToxRef Database. Environ. Health Perspect. 2009, 117:392-399.
35. Martin M.T., Mendez E., Corum D.G., Judson R.S., Kavlock R.J., Rotroff D.M., Dix D.J. Profiling the reproductive toxicity of chemicals from multigeneration studies in the toxicity reference database. Toxicol. Sci. 2009, 110:181-190.
36. Muindi J.R., Frankel S.R., Huselton C., DeGrazia F., Garland W.A., Young C.W., Warrell R.P. Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Cancer Res. 1992, 52:2138-2142.
37. Muller M., Mader R.M., Steiner B., Steger G.G., Jansen B., Gnant M., Helbich T., Jakesz R., Eichler H.G., Blochl-Daum B. 5-fluorouracil kinetics in the interstitial tumor space: clinical response in breast cancer patients. Cancer Res. 1997, 57:2598-2601.
38. Nachmany A., Gold V., Tsur A., Arad D., Weil D. Neural tube closure depends on nitric oxidase synthase activity. J. Neurochem. 2006, 96:247-253.
39. Nelson M.M., Wright H.V., Baird C.D., Evans H.M. Teratogenic effects of pantothenic acid deficiency in the rat. J. Nutr. 1957, 62:395-405.
40. Noguchi T., Fujimoto H., Sano H., Miyajima A., Miyachi H., Hashimoto Y. Angiogenesis inhibitors derived from thalidomide. Bioorg. Med. Chem. Lett. 2005, 15:5509-5513.
41. Prince J.T., Marcotte E.M. Chromatographic alignment of ESI-LC-MS proteomics data sets by ordered bijective interpolated warping. Anal. Chem. 2006, 78:6140-6152.
42. Repine J., Bast A., Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1997, 156:341-357. Group, O. S. S.
43. Rock C., Calder R., Karim M., Jackowski S. Pantothenate kinase regulation of the intracellular concentration of coenzyme A. J. Biol. Chem. 2000, 275:1377-1383.
44. Rotroff D.M., Beam A.L., Dix D.J., Farmer A., Freeman K.M., Houck K.A., Judson R.S., LeCluyse E.L., Martin M.T., Reif D.M., Ferguson S.S. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J. Toxicol. Environ. Health B Crit. Rev. 2010, 13:329-346.
45. Sabatine M.S., Liu E., Morrow D.A., Heller E., McCarroll R., Wiegand R., Berriz G.F., Roth F.P., Gerszten R.E. Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation 2005, 112:3868-3875.
46. Seiler A.E., Buesen R., Visan A., Spielmann H. Use of murine embryonic stem cells in embryotoxicity assays: the embryonic stem cell test. Methods Mol. Biol. 2006, 329:371-395.
47. Seth V., Seth S.D., Beotra A., Semwal O.P., D'Monty V., Mukhopadhya S. Isoniazid and acetylisoniazid kinetics in serum and urine in pulmonary primary complex with intermittent regimen. Indian Pediatr. 1994, 31:279-285.
48. Shoda H., Inokuma S., Yajima N., Tanaka Y., Oobayashi T., Setoguchi K. Higher maximal serum concentration of methotrexate predicts the incidence of adverse reactions in Japanese rheumatoid arthritis patients. Mod. Rheumatol. 2007, 17:311-316.
49. Simonian N., Coyle J. Oxidative stress in neurodegenerative diseases. Annu. Rev. Pharmacol. Toxicol. 1996, 36:83-106.
50. Smith C.A., Want E.J., O'Maille G., Abagyan R., Siuzdak G. XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal. Chem. 2006, 78:779-787.
51. Tan D.X., Manchester L.C., Reiter R.J., Plummer B.F., Hardies L.J., Weintraub S.T., Vijayalaxmi, Shepherd A.M. A novel melatonin metabolite, cyclic 3-hydroxymelatonin: a biomarker of in vivo hydroxyl radical generation. Biochem. Biophys. Res. Commun. 1998, 253:614-620.
52. Tautenhahn R., Bottcher C., Neumann S. Highly sensitive feature detection for high resolution LC/MS. BMC Bioinformatics 2008, 9:504.
53. Thornalley P.J., Babaei-Jadidi R., Al Ali H., Rabbani N., Antonysunil A., Larkin J., Ahmed A., Rayman G., Bodmer C.W. High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease. Diabetologia 2007, 50:2164-2170.
54. Torano J.S., Verbon A., Guchelaar H.J. Quantitative determination of thalidomide in human serum with high-performance liquid chromatography using protein precipitation with trichloroacetic acid and ultraviolet detection. J. Chromatogr. B Biomed. Sci. Appl. 1999, 734:203-210.
55. Tveden-Nyborg P., Johansen L.K., Raida Z., Villumsen C.K., Larsen J.O., Lykkesfeldt J. Vitamin C deficiency in early postnatal life impairs spatial memory and reduces the number of hippocampal neurons in guinea pigs. Am. J. Clin. Nutr. 2009, 90:540-546.
56. Walsh S. Maternal-placental interactions of oxidative stress and antioxidants in preeclampsia. Semin. Reprod. Med. 1998, 16:93-104.
57. Weinstein H.J., Griffin T.W., Feeney J., Cohen H.J., Propper R.D., Sallan S.E. Pharmacokinetics of continuous intravenous and subcutaneous infusions of cytosine arabinoside. Blood 1982, 59:1351-1353.
58. West P.R., Weir A.M., Smith A.M., Donley E.L.R., Cezar G.G. Predicting human developmental toxicity of pharmaceuticals using human embryonic stem cells and metabolomics. Toxicol. Appl. Pharmacol. 2010, 247:18-27.
59. Zhao W., Mosley B., Cleves M., Melnyk S., James S., Hobbs C. Neural tube defects and maternal biomarkers of folate, homocysteine, and glutathione metabolism. Birth Defects Res. A Clin. Mol. Teratol. 2006, 76:230-236.
60. Zwaveling J., Bredius R.G., Cremers S.C., Ball L.M., Lankester A.C., Teepe-Twiss I.M., Egeler R.M., den Hartigh J., Vossen J.M. Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity. Bone Marrow Transplant. 2005, 35:17-23.